Amarin Corp. (AMRN) Tops Q4 EPS by 4c, Revs Beat; Reaffirms
Amarin Corp. (NASDAQ: AMRN) reported Q4 EPS of $0.02, $0.04 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $143.3 million versus the consensus estimate of $136.01 million.
“2019 was a transformational year for Amarin and for preventative cardiovascular patient care,” commented John Thero, Amarin’s president and chief executive officer. “VASCEPA became the first and only FDA approved therapy for its new cardiovascular risk reduction indication. Our record 2019 revenue levels, together with the recent FDA-approved VASCEPA label expansion, excellent employees and strong third-party support, all position Amarin for considerably further growth in 2020 and beyond. Based on feedback thus far, we are confident that healthcare professionals will appreciate the clinical effectiveness and safety profile of VASCEPA and that they will agree that many patients can benefit from this unique product. In 2020, we plan to prioritize market education and promotion to expand the usage of VASCEPA for the benefit of at-risk patients. This is the advent of a new era in preventative cardiovascular care.”
Amarin Corp. reaffirms FY2020 revenue of $650-700 million, versus the consensus of $695.43 million.
For earnings history and earnings-related data on Amarin Corp. (AMRN) click here.